Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Sclerosis
Interventions
GLP-1, Ocrelizumab (US)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Relapsing Multiple Sclerosis
Interventions
CYB704, Ocrevus-EU, Ocrevus-US
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Ormond Beach, Florida
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
Ocrelizumab (US), Ocrelizumab (EU), ABP 692
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Scottsdale, Arizona • Carlsbad, California + 24 more
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Remibrutinib, Ocrelizumab (US)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri